Prasad Suyash's Form 4 filing
Taysha Gene Therapies, Inc. (TSHA) · filed Jul 7, 2022
- Accession no.
- 0001209191-22-041455
- Filed
- Jul 7, 2022
- Trade date
- Jul 5-6, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $47.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Prasad SuyashCIK 0001679129 | Officer (CMO and Head of R&D) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 5, 2022 | Common Stock | SSaleDisposed | −3,905 | $3.51 | −$13,706.55 | 539,545 | Direct | |
| Jul 6, 2022 | Common Stock | SSaleDisposed | −8,956 | $3.79 | −$33,943.24 | 530,589 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.